1. Nilsson S, Larsen RH, Foss SD, Balteskard L, Borch KW, Westlin J-E, et al. First clinical experience with α-emitting radium-223 in the treatment of skeletal metastases. Clin. Cancer Res. 2005; 12(12):4451-9.
2. Hindorf C, Chittenden S, Aksnes A-K, Parker C, Chris F, Glenn D. Quantitative imaging of 223Ra-chloride (Alpharadin) for targeted alpha-emitting radionuclide therapy of bone metastases. Nucl. Med. Commun. 2012; 33(7):726-32.
3. Carrasquillo JA, O’Donoghue JA, Taskar NP, Humm JL, Rathkopf DE, Slovin SF, et al. Phase I pharmacokinetic and biodistribution study with escalating doses of 223Ra-dichloride in men with castration-resistant metastatic prostate cancer. Eur. J. Nucl. Med. Mol. Imaging 2013; 40(9):1384-93.
4. Lassmann M, Nosske D. Dosimetry of 223Ra-chloride: dose to normal organs and tissues. Eur. J. Nucl. Med. Mol Imaging 2013; 40(2):207-12.
5. Chittenden SJ, Hindorf C, Parker CC, Lewington VJ, Pratt BE, Johnson B, et al. A Phase 1, open-label study of the biodistribution, pharmaco-kinetics, and dosimetry of 223Ra-dichloride in patients with hormone-refractory prostate cancer and skeletal metastases. J. Nucl. Med. 2015; 56(9):1304-9.
6. Pacilio M, Ventroni G, Cassano B, Ialongo P, Lorenzon L, Castro ED, et al. A case report of image-based dosimetry of bone metastases with Alpharadin (223Ra-dichloride) therapy: inter-fraction variability of absorbed dose and follow-up. Ann. Nucl. Med. 2016; 30(2):163-8.
7. Yoshida K, Kaneta T, Takano S, Sugiura M, Kawano T, Hino A, et al. Pharmacokinetics of single dose radium-223 dichloride (BAY 88-8223) in Japanese patients with castration-resistant prostate cancer and bone metastases. Ann. Nucl. Med. 2016; 30(7):453-60.
8. Pacilio M, Ventroni G, De Vincentis G, Cassano B, Pellegrini R, Di Castro E, et al. Dosimetry of bone metastases in targeted radionuclide therapy with alpha-emitting 223Ra-dichloride. Eur. J. Nucl. Med. Mol. Imaging 2016; 43(1):21-33.
9. Umeda T, Koizumi M, Fukai S, Miyaji N, Motegi K, Nakazawa S, et al. Evaluation of bone metastatic burden by bone SPECT/CT in metastatic prostate cancer patients: defining threshold value for total bone uptake and assessment in radium-223 treated patients. Ann. Nucl. Med. 2018; 32(2):105-13.
10. Pibida L, Zimmerman B, Fitzgerald R, King L, Cessna JT, Bergeron DE. Determination of photon emission probabilities for the main gamma-rays of 223Ra in equilibrium with its progeny. Appl. Radiat. Isot. 2015; 101(1):15-9.
11. Takahashi A, Miwa K, Sasaki M, Baba S. A Monte Carlo study on 223Ra imaging for unsealed radionuclide therapy. Med. Phys. 2016; 43(6):2965-74.
12. Owaki Y, Nakahara T, Kosaka T, Fukada J, Kumabe A, Ichimura A, et al. Ra-223 SPECT for semi-quantitative analysis in comparison with Tc-99m HMDP SPECT: phantom study and initial clinical experience. EJNMMI Research 2017; 7:81.
13. Benabdallah N, Bernardini M, Bianciardi M, de Labriolle-Vaylet C, Franck D, Desbrée A. 223Ra-dichloride therapy of bone metastasis: optimization of SPECT images for quantification. EJNMMI Res. 2019; 9:20
14. Gustafsson J, Rodeño E, Mınguez P. Feasibility and limitations of quantitative SPECT for 223Ra. Phys. Med. Biol. 2020;65(8):085012.
15. Yue J, Hobbs R, Sgouros S, Frey E. Quantitative SPECT Imaging of Ra‐223 in a Phantom. Med. Phys. 2016; 43(Issue 6 Part8):3407.
16. Takahashi A, Baba S, Sasaki M. Assessment of collimators in radium-223 imaging with channelized Hotelling observer: a simulation study. Ann. Nucl. Med. 2018; 32(10): 649-57.
17. Tanaka M, Uehara S, Kojima A, Matsumoto M. Monte Carlo simulation of energy spectra for 123I imaging. Phys. Med. Biol. 2007; 52(15):4409-25.
18. Cherry SR, Sorenson JA, Phelps ME. Physics in Nuclear Medicine. 3rd edition, Pennsylvania: Elsevier; 2003, p263-265.
19. Segars WP, Sturgeon G, Mendonca S, Grimes J, Tsui BMW. 4D XCAT phantom for multimodality imaging research. Med. Phys. 2010; 37(9):4902-15.
20. Cherry SR, Sorenson JA, Phelps ME. Physics in Nuclear Medicine. 3rd edition, Pennsylvania: Elsevier; 2003, p83.